可复美重组胶原蛋白敷料

Search documents
美容护理行业深度报告:胶原蛋白:成分崛起,美丽新生
Donghai Securities· 2025-08-05 08:49
Investment Rating - The report suggests a focus on companies in the recombinant collagen sector, highlighting their potential for growth and market leadership [5][6]. Core Insights - Collagen is essential for human health, providing structural support and biological functions [11][14]. - The domestic recombinant collagen technology is advanced, with a complete industrial chain and supportive policies driving growth [6][31]. - The market for recombinant collagen is expected to grow significantly, with a projected CAGR of 41.4% from 2023 to 2027, surpassing the growth of animal-derived collagen [6][27]. - The applications of collagen are diverse, including medical aesthetics, skincare, intimate health, and hair health [6][33]. Summary by Sections 1. Collagen as a Vital Component - Collagen constitutes 30%-40% of human protein and is crucial for skin, bones, tendons, and ligaments [11][14]. - There are at least 29 types of collagen in the human body, with types I and III being the most common in the skin [14][15]. 2. Production: Recombinant vs. Animal-Derived Collagen - Recombinant collagen is produced using gene engineering, offering advantages such as no virus risk and better biocompatibility compared to animal-derived collagen [19][26]. - The market for recombinant collagen is expected to reach 286.3 billion yuan in 2023, with a significant growth trajectory [27][28]. 3. Policy Support for Market Development - The regulatory framework for recombinant collagen has been improving, with various guidelines issued since 2021 to standardize the industry [31][32]. 4. Diverse Applications of Recombinant Collagen - **Medical Aesthetics**: The market for recombinant collagen in medical aesthetics is projected to grow from 43 billion yuan in 2023 to 143 billion yuan by 2027, with a CAGR of 35.4% [6][42]. - **Skincare**: The market for functional skincare products containing recombinant collagen is expected to grow from 115 billion yuan in 2023 to 665 billion yuan by 2027, with a CAGR of 54.9% [47][49]. - **Intimate Health**: The market for intimate health products is anticipated to grow significantly, driven by increasing consumer awareness and demand [51][52]. 5. Key Companies in the Industry - **Jinbo Biological**: A leader in recombinant collagen with unique medical aesthetic products [5][40]. - **Juzi Biological**: Known for its brands Kefu Mei and Keli Jin, actively expanding its medical aesthetic pipeline [5][40]. - **Marubi Biological**: Accelerating its research in collagen, with significant product launches [5][40].
可复美再塌房,巨子生物急渡劫
3 6 Ke· 2025-06-13 09:11
Core Insights - The medical beauty industry in China is projected to grow, with a consumption penetration rate increasing from 3.2% in 2020 to 5.8% by 2025, indicating over 80 million people have undergone medical beauty procedures [1] - The brand "可复美" (Kefumei) under 巨子生物 (Giant Bio) is facing significant negative publicity due to allegations of product fraud related to its key ingredient, recombinant collagen [2][3] - The controversy has led to a substantial decline in Giant Bio's stock price, dropping nearly 30% from its peak of 87.1 HKD [3][25] Industry Overview - The medical beauty market is expanding rapidly, with a notable increase in consumer engagement and product usage [1] - The competitive landscape is intensifying, particularly with rival companies like 华熙生物 (Huaxi Bio) actively targeting Giant Bio amid the ongoing controversies [4][5] Company Performance - Giant Bio's revenue grew from 20 billion RMB in 2022 to 35.24 billion RMB in 2023, marking a 49.05% increase, and further to 55.39 billion RMB in 2024, with a 57.2% year-on-year growth [25] - Despite strong revenue growth, the company has faced challenges in maintaining investor confidence due to recent scandals, leading to a market capitalization drop of over 60 billion HKD [3][25] Product Controversies - The allegations against Kefumei include claims that the amount of recombinant collagen in its products is significantly lower than advertised, raising questions about product integrity [3][6] - Previous controversies involved undisclosed ingredients like epidermal growth factor (EGF), which is banned in cosmetic products, further complicating the brand's reputation [10][12][17] Market Dynamics - The ongoing disputes have prompted consumers to reconsider their loyalty to Kefumei, with potential shifts towards alternative brands like 修丽可 (Xiu Li Ke) and 敷尔佳 (Fu Er Jia) [27] - The company's reliance on sales and marketing over research and development is evident, with a stark contrast between sales expenses and R&D investment, which may impact long-term sustainability [28][29]
股价大跌!美妆龙头遭质疑,公司回应!多家券商研报被“声讨”
证券时报· 2025-05-26 09:05
Core Viewpoint - The article discusses allegations against Juzi Biotechnology regarding the authenticity of its recombinant collagen products, leading to a significant drop in its stock price and market value [1][2][4][8]. Group 1: Allegations and Responses - Beauty influencer "Big Mouth Doctor" accused Juzi Biotechnology of serious fraud, claiming that its recombinant collagen serum could not be detected as advertised, with a reported collagen content of only 0.0177% [1][8][9]. - Juzi Biotechnology's brand, Kefu Mei, firmly denied these allegations, stating that their product tests showed collagen content exceeding 0.1%, and they have engaged third-party testing agencies for further verification [4][12]. Group 2: Financial Impact - Following the allegations, Juzi Biotechnology's stock opened down over 8% and closed with a decline of 4.04%, resulting in a market capitalization below 800 billion HKD [2]. - The company has experienced rapid revenue growth, with a reported revenue increase from 9 billion to 55 billion CNY from 2019 to 2024, and a net profit rise from 5.5 billion to 20.6 billion CNY during the same period [15][16]. Group 3: Company Background and Market Position - Juzi Biotechnology, led by Fan Daidi, a vice president of Northwest University, is a leader in the recombinant collagen sector, with a product range that includes functional skincare, medical dressings, and medical devices [14][16]. - The company has established a strong market presence, with its products available in 1,700 public hospitals, 3,000 private hospitals and clinics, and 6,000 cosmetic specialty stores [14]. Group 4: Industry Context - The recombinant collagen and medical beauty sectors are characterized by high profit margins, with Juzi Biotechnology boasting a gross margin of 82% [16]. - The industry has seen significant interest and investment, with Juzi Biotechnology's IPO in 2022 raising 584 million HKD and subsequent financing rounds in 2024 raising over 16 billion HKD [16].
旗下可复美陷“造假门”!巨子生物开盘跌超8%,A股重组蛋白概念股下跌
Mei Ri Jing Ji Xin Wen· 2025-05-26 02:24
Core Viewpoint - The stock price of Giant Bio (HK02367) experienced a significant decline following allegations of product fraud related to its brand, Kefu Mei, which led to a public statement denying the accusations and asserting compliance with regulatory standards [9][10]. Group 1: Company Performance - As of May 26, Giant Bio's stock opened with a drop exceeding 8%, later narrowing to a decline of 3.52% [1]. - The company's market capitalization is approximately 80 billion HKD [11]. - Kefu Mei, a brand under Giant Bio, reported sales revenue exceeding 4.5 billion CNY in 2024, reflecting a year-on-year growth of 62.9% [10]. Group 2: Industry Context - The A-share market saw a collective decline in stocks related to recombinant protein, with notable drops in companies such as Ruizhi Pharmaceutical and Sanofi Guojian, each falling nearly 6% [2]. - The market reaction indicates a broader concern regarding the credibility of companies in the recombinant protein sector following the allegations against Giant Bio [2].
知名医美巨头涉嫌严重造假?回应来了
新华网财经· 2025-05-25 04:43
Core Viewpoint - The company "可复美" (Kefumei) strongly denies allegations regarding the lack of recombinant collagen protein in its products, asserting compliance with relevant regulations and standards [1][2][3]. Group 1: Company Response to Allegations - Kefumei refutes claims of serious fraud and emphasizes that all product development and production adhere to the "Cosmetics Supervision and Administration Regulations" and related laws [1]. - The company confirms that all products undergo a three-tier verification system, including raw material checks, production quality control, and finished product testing, ensuring product safety and reliability [1]. - Initial internal testing showed collagen protein content exceeding 0.1%, contradicting the alleged 0.0177% [1][2]. Group 2: Regulatory Compliance and Standards - According to the National Medical Products Administration's "Cosmetics Labeling Management Measures," ingredients must be listed in descending order based on their content, with those below 0.1% labeled as "other trace ingredients" [2]. - The product in question has a soluble collagen content greater than 0.1%, thus it is listed as a main ingredient, further disputing the claims of low content [2]. Group 3: Third-Party Testing and Industry Standards - To address consumer concerns, Kefumei has engaged multiple authoritative third-party testing agencies to conduct further testing, which will be reported once available [3]. - The company notes that the testing methods used by the accusers are not recognized by industry standards, rendering their results unreliable [3]. - The National Medical Products Administration is working on establishing industry standards for recombinant collagen protein testing, and Kefumei is actively participating in this initiative [3]. Group 4: Company Performance - Kefumei, a brand under the publicly listed company 巨子生物 (Giant Bio), reported sales revenue exceeding 4.5 billion yuan, marking a 62.9% year-on-year increase [4]. - As of May 23, the market capitalization of Giant Bio exceeded 80 billion Hong Kong dollars [4].
科创致富!西北大学范代娣夫妇新一任陕西首富|热聊
Sou Hu Cai Jing· 2025-05-14 06:57
Core Insights - The article highlights the rise of Fan Daidi, the new vice president of Northwest University, who has become the richest person in Shaanxi province due to her and her husband's successful ventures in the biotechnology and defense sectors [1][3]. Company Overview - Fan Daidi and her husband, Yan Jianya, control two publicly listed companies: Juzhi Biotechnology and Triangle Defense, with market capitalizations of approximately 882.96 billion HKD and 143 billion HKD, respectively, as of May 13 [1][3]. - Juzhi Biotechnology is recognized as China's largest collagen protein company, achieving a revenue of 5.539 billion CNY in 2022, a year-on-year increase of 57.2%, and a net profit of 2.062 billion CNY, up 42.1% [1][11]. Industry Position - Juzhi Biotechnology operates in the high-margin field of recombinant collagen, with a gross margin of 82.09% [1][11]. The company has expanded its product offerings to include medical dressings and functional foods, positioning itself as a leader in the beauty and medical skincare market [11]. - The company has been referred to as the "Moutai for women," indicating its high profitability and market demand [11]. Financial Performance - Juzhi Biotechnology has seen rapid growth, with revenue increasing from 900 million CNY in 2019 to 5.539 billion CNY in 2022, and net profit rising from 550 million CNY to 2.062 billion CNY during the same period [11]. - Despite high growth and profitability, the company has engaged in frequent financing activities, raising a total of 4.56 billion HKD since its IPO in 2022 [13]. Leadership and Innovation - Fan Daidi has made significant contributions to the field of recombinant collagen, holding numerous patents and awards, including the National Technology Invention Award [9][11]. - Yan Jianya, initially a chemical engineering teacher, transitioned into the defense sector by founding Triangle Defense, which focuses on providing services to the national defense industry [5][7].
一片面膜40元,陕西女富豪年赚20亿
创业家· 2025-04-27 10:18
以下文章来源于财经天下WEEKLY ,作者财经天下 财经天下WEEKLY . 《财经天下》周刊官方账号,提供有品质的深度报道,讲述中国企业在时代浪潮中的精彩故事。 毛利率在80%以上,研发投入却较低。 作者:林木 编辑:吴跃 来源:财经天下WEEKLY 因为陷入"EGF(表皮生长因子)罗生门",可复美近期被推上风口浪尖。 不久前,有消费者反映可复美产品"违规添加EGF"。随后可复美母公司巨子生物予以否认, 称"旗下所有产品均未添加"。伴随着舆论发酵,社媒平台上,看客们吵得沸沸扬扬,力挺声、 质疑声四起,也让"可复美"这个名字被更多人知晓。 做过医美或者皮肤敏感的消费者,大多对"可复美"三个字不陌生。这个主打皮肤修复的品牌, 早年间主要深耕院线渠道,之后乘上直播电商风口,进入更多人视野,撬开更多钱包。过去6 年,其母公司巨子生物营收从9.57亿元涨至55.39亿元,翻了5倍多。 2024年,巨子生物一举超越珀莱雅,成为市值最高的国货美妆公司,此后一直保持至今。公 司创始人,现年59岁的陕西人范代娣,也因此登顶国货美妆首富。 爱美的女生,这些年托举过不少美妆公司。当下风头最盛的可复美和巨子生物,到底是何来 头?为 ...